Arthur E. Reyes - Concepedia

Author

Arthur E. Reyes

Acentech (United States)

Also Known As

A Reyes, A. Reyes, A.E. Reyes, Arthur E. Reyes, Arthur E. Reyes II, Arthur Reyes

Publications

686

Citations

H-Index

Concepts

All Affiliations

Acentech (United States)

About

Arthur E. Reyes is an author at Acentech (United States) specializing in medicine, immunotherapy, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	247
2	Engineering	1	1	109
3	Biomedical Engineering	1	1	109
4	Cell Biology	1	1	109
5	Cellular Physiology	1	1	109

Arthur E. Reyes

Publications

671

Citations

H-Index

Page 1

	Year	Citations
Anti-CD20/CD3 T cell–dependent bispecific antibody for the treatment of B cell malignancies Liping Sun, Diego Ellerman, Mary Mathieu, Science Translational Medicine	2015	269
Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4 Daniela Bumbaca, Anne Wong, Elizabeth A. Drake, mAbs Immunocytochemical TechniqueImmunologyTherapeutic AntibodyImmunotherapyCancer Biology	2011	109
Performance of small-scale CHO perfusion cultures using an acoustic cell filtration device for cell retention: Characterization of separation efficiency and impact of perfusion on product quality Thomas Ryll, George Dutina, Arthur E. Reyes, Biotechnology and Bioengineering EngineeringCell CulturePerfusion ModeBiomedical EngineeringCellular Physiology	2000	109
A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life Yik A. Yeung, Xiumin Wu, Arthur E. Reyes, Cancer Research	2010	76
A Preclinical Population Pharmacokinetic Model for Anti‐CD20/CD3 T‐Cell‐Dependent Bispecific Antibodies Gregory Z. Ferl, Arthur E. Reyes, Liping Sun, Clinical and Translational Science	2018	35
Onartuzumab (MetMAb): Using Nonclinical Pharmacokinetic and Concentration–Effect Data to Support Clinical Development Hong Xiang, Brendan C. Bender, Arthur E. Reyes, Clinical Cancer Research	2013	34
Pharmacodynamic assessment of dihydroxyprogesterone acetophenide plus estradiol enanthate as a monthly injectable contraceptive R. Recio, J. Garza‐Flores, Raffaela Schiavon, Contraception ContraceptionEstradiol EnanthateHormonal ContraceptiveOral ContraceptiveDihydroxyprogesterone Acetophenide	1986	18
Death receptor 5 agonistic antibody PRO95780: preclinical pharmacokinetics and concentration–effect relationship support clinical dose and regimen selection Hong Xiang, Arthur E. Reyes, Steve Eppler, Cancer Chemotherapy and Pharmacology ImmunologyPharmacologyClinical TrialsRegimen SelectionTherapeutic Efficacy	2013	11
Nonclinical Pharmacokinetics and Pharmacodynamics Characterization of Anti-CD79b/CD3 T Cell-Dependent Bispecific Antibody Using a Surrogate Molecule: A Potential Therapeutic Agent for B Cell Malignancies Rajbharan Yadav, Siddharth Sukumaran, Tanja S. Zabka, Pharmaceutics	2022	10

Page 1